share_log

Core One's Vocan Files International Patent for Its Breakthrough Proprietary Biosynthetic Psilocybin Production Method

Core One's Vocan Files International Patent for Its Breakthrough Proprietary Biosynthetic Psilocybin Production Method

Core One的Vocan憑藉其突破性的專有生物合成psilocybin生產方法申請國際專利
Accesswire ·  2023/07/08 05:55

VANCOUVER, BC / ACCESSWIRE / July 7, 2023 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6), (WKN: A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly owned subsidiary, Vocan Biotechnologies Inc. ("Vocan"), has completed final steps of its research for its biosynthetic production system (the System) and has filed a patent under the Patent Cooperation Treaty (PCT) (the "Patent" or "Filing") for international protection of its novel production techniques for biosynthesized psilocybin (the "Invention").

不列顛哥倫比亞省溫哥華/ACCESSWIRE/2023年7月7日/ Core One實驗室公司(CSE:涼爽的)、(OTCQB:CLABF)、(法蘭克福:LD6)、(WKN:A3CSSU)(“公司“或”核心一“)很高興地宣佈其全資子公司Vocan BioTechnologies Inc.(“Vocan),已完成其生物合成生產系統(系統)的最後研究步驟,並已根據專利合作條約(PCT)申請專利(專利“或”歸檔“)國際保護其生物合成裸蓋菇素的新生產技術(The”發明創造“)。

Vocan's filling of this international patent is a monumental step in the patenting of its revolutionary biosynthetic psilocybin production method. Prior to the PCT patent, Vocan had filed a provisional patent (the "Provisional Patent") with the United States Patent and Trademark Office (the "USPTO") in January 2022, outlining its theory for a proprietary biosynthetic psilocybin production process. Over the past year, Vocan scientists have been able to prove their concept through rigorous experimentation and testing, successfully documenting and defending the breakthrough production method. The summation of Vocan's findings has resulted in today's announced international patent filing, the success of which will ensure Vocan's revolutionary biosynthetic production system for psilocybin would remain the exclusive property of the Company.

Vocan填補這一國際專利是其革命性的生物合成裸蓋菇素生產方法獲得專利的重要一步。在獲得PCT專利之前,Vocan已於2022年1月向美國專利商標局(USPTO)提交了臨時專利(“臨時專利”),概述了其專有生物合成裸蓋菇素生產工藝的理論。在過去的一年裡,Vocan的科學家們通過嚴格的實驗和測試證明瞭他們的概念,成功地記錄和捍衛了這種突破性的生產方法。綜合Vocan的發現,今天宣佈了國際專利申請,該專利的成功將確保Vocan革命性的裸蓋菇素生物合成生產系統將仍然是該公司的獨家財產。

This filing marks a major milestone in the Company's progression towards becoming an industry frontrunner in the psychedelic space as a leading producer of psychedelic drugs, given Core One's proprietary production systems having the ability to yield 100% pure API grade psilocybin through an extremely cost and time efficient method. The current market price of reliable API and GMP compliant psilocybin, produced via conventional synthetic and extraction/isolation production methods, ranges between US$7,000 - US$10,000 per gram.1 The Company's novel recombinant System can cut production costs significantly with increased efficiency, which could, as a result, lead to substantially lower market price of API and GMP compliant psilocybin and potentially transform psychedelic-based mental health care worldwide.

鑑於Core One的專有生產系統能夠通過極具成本和時間效益的方法生產100%純原料藥原料級裸蓋菇素,這一申請標誌著該公司成為迷幻藥物領域的行業領先者的進程中的一個重要里程碑。目前,通過傳統的合成和提取/分離生產方法生產的符合原料藥和GMP標準的裸蓋菇素的市場價格在每克7,000-10,000美元之間。1該公司的新型重組系統可以大幅削減生產成本,提高效率,從而大幅降低符合原料藥和GMP標準的裸蓋菇素的市場價格,並有可能在全球範圍內改變以迷幻藥為基礎的精神衛生保健。

The Patent is a result of a culmination of three (3) years of diligent research and trials, conducted and perfected by Vocan's team of scientists, and holds considerable importance for the Company and its investors, since the Patent's success will enhance and solidify Core One's ability to protect its Invention across many countries; and as a result, prevent it from being copied and manipulated by competitors.

這項專利是Vocan的科學家團隊經過三(3)年勤奮研究和試驗的結果,對公司及其投資者具有相當重要的意義,因為這項專利的成功將增強和鞏固Core One在許多國家和地區保護其發明的能力,從而防止它被競爭對手複製和操縱。

The Provisional Patent detailed a proof-of-concept production method for the biosynthetic production of psychedelic compounds, whereby its scientists used a recombinant protein expression process technology to convert a chosen bacterial strain into a production factory to produce psilocybin (the "Production Method"). The Production Method utilized by Vocan effectively inserts and manipulates DNA segments to add to the genetic make-up of the chosen bacteria, so that the bacteria contain appropriate biosynthetic enzymes (proteins that help to catalyze and speed up chemical reactions in the bacteria) and allow the organism to produce psilocybin at yields that Vocan scientists have deemed suitable for scale-up production capabilities.

臨時專利詳細介紹了一種用於生物合成迷幻化合物的概念驗證生產方法,即其科學家使用重組蛋白表達過程技術將選定的細菌菌株轉化為生產工廠以生產裸蓋菇素(“生產方式”Vocan使用的生產方法有效地插入和操縱DNA片段,以增加所選細菌的遺傳組成,使細菌包含適當的生物合成酵素(有助於催化和加快細菌中化學反應的蛋白質),並使微生物能夠以Vocan科學家認為適合擴大生產能力的產量生產裸蓋菇素。

"The filling of the international patent is the biggest achievement Vocan has made to date. Since the inception of Vocan, its team of scientists have been dedicated to completing the work required to file this patent. Now that this milestone has been completed, the Company will focus on refining the biosynthetic production process to increase yield and decrease cost," stated Joel Shacker, Core One CEO.

Core One首席執行官喬爾·沙克說:“填補國際專利是Vocan迄今取得的最大成就。自Vocan成立以來,其科學家團隊一直致力於完成申請這項專利所需的工作。現在這一裡程碑已經完成,公司將專注於改進生物合成生產過程,以提高產量和降低成本。”

About Core One Labs Inc.

Core One Labs Inc.簡介

Core One Labs is a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of novel delivery systems technology.

Core One Labs是一家生命科學生物技術研發公司,專注於通過迷幻化合物的開發和生產、迷幻輔助治療的進步以及新型遞送系統技術的集成,將迷幻藥物推向市場。

The Company has a multi-faceted business approach and incorporates several complementary lines of businesses and units in establishing itself as an industry leader in the rapidly growing and emerging psychedelics market space.

該公司擁有多方面的業務方法,併合並了幾個互補的業務和部門,以確立其作為快速增長和新興的迷幻藥市場領域的行業領先者的地位。

Core One, through its wholly owned subsidiary Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of 4 provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its 100% owned subsidiary Akome Biotech Ltd., and 3 provisional patents under its other 100% owned subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods.

Core One通過其全資子公司Vocan BioTechnologies Inc.開發了一種使用工程菌生產裸蓋菇素的專有系統,並申請了專利保護。它還持有4項臨時專利,用於開發針對神經和精神健康障礙的迷幻藥物配方,由其100%擁有的子公司Akome Biotech Ltd.擁有,並擁有3項臨時專利,由其另一家100%擁有的子公司Awaded Biosciences Inc.擁有,用於開發裸蓋菇素和裸蓋菇素生產方法的其他合成技術。

In addition to the development of psychedelics and psychedelic compounds, Core One holds an interest in four medical clinics which maintain a combined database of more than 275,000 patients. Through its clinics the Company intends to integrate a roll out of its intellectual property related to psychedelic technologies and participate in the advancement of psychedelic-based treatments for mental health disorders.

除了開發迷幻劑和迷幻化合物外,Core One還持有四家醫療診所的股份,這四家診所維護著一個超過275,000名患者的綜合資料庫。通過其診所,該公司打算整合其與迷幻技術相關的知識產權的推出,並參與推進基於迷幻藥物的精神健康障礙治療。

Core One Labs Inc.

Core One實驗室公司

Joel Shacker
Chief Executive Officer

喬爾·謝克
首席執行官

FOR MORE INFORMATION, PLEASE CONTACT:
info@core1labs.com
1-888-452-6731

如需更多資訊,請聯繫:
郵箱:Info@core1Labs.com
1-888-452-6731

Cautionary Disclaimer Statement:

謹慎免責聲明:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

加拿大證券交易所沒有對本新聞稿內容的充分性或準確性進行審查,也不承擔任何責任。

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

本新聞稿中的資訊包含前瞻性陳述,這些陳述基於截至本新聞稿發佈之日的假設。這些陳述反映了管理層當前的估計、信念、意圖和期望。它們並不是未來業績的保證。公司提醒,所有前瞻性陳述本身都是不確定的,實際表現可能會受到許多重大因素的影響,其中許多因素不是公司所能控制的。這些因素包括但不限於:與該公司有限的經營歷史有關的風險和不確定因素,以及遵守嚴格監管規定的必要性。因此,實際和未來的事件、條件和結果可能與前瞻性資訊中明示或暗示的估計、信念、意圖和預期大不相同。除非適用的證券法規另有要求,否則公司沒有義務公開更新或修改前瞻性資訊。

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

此外,裸蓋菇素目前是《聯合國憲章》第三類藥物。《受管制藥物和物質法》(加拿大),擁有《公約》規定的物質是刑事犯罪。《受管制藥物和物質法》(加拿大)沒有處方或授權的。加拿大衛生部尚未批准裸蓋菇素作為任何適應症的藥物。Core One不直接或間接參與在其運營的司法管轄區非法銷售、生產或分銷迷幻藥物。雖然Core One認為迷幻物質可以用於治療某些醫療疾病,但它並不主張娛樂用途的迷幻物質合法化。CORE One不涉及致幻物質,除非在經批准的監管框架內進行的實驗室和臨床試驗。

1Psilocybin - Current Market Prices

1裸蓋菇素--當前市場價格

SOURCE: Core One Labs Inc.

資料來源:Core One實驗室公司


View source version on accesswire.com:
在Accesswire.com上查看源代碼版本:

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論